NEW YORK (GenomeWeb News) – Transgenomic said in a document filed with the US Securities and Exchange Commission this week that its shareholders have approved an increase in the number of authorized shares of the firm's common stock from 100 million to 150 million.


Fluxion Biosciences said this week that it has launched its discovery services business, which will offer a range of cellular assays in ion channels using its IonFlux system, functional cell analysis using its BioFlux system, and circulating tumor cell analysis using its IsoFlux platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.